The collective experience that our Board of Directors brings to SpectraGenics provides us with unparalleled expertise from a wide range of industries including laser technology, financial services, health care, beauty and personal care.

Robert E. Grove, Ph.D. President and CEO, SpectraGenics, Inc.
•	Ph.D., M.I.T. (1975)
•	Co-founder of three previous start-ups, all involving aesthetic lasers
•	Former president of Star Medical Technologies, direct responsibility for $60M/yr worldwide aesthetic laser business

Albert Cha, M.D., Ph.D. Managing Partner, Vivo Ventures http://www.vivoventures.com
•	Serves or has served on the boards of Biodel (NASDAQ: BIOD) and Bioform Medical (NASDAQ: BFRM) as well as several private biotechnology and medical device companies
•	Prior professional experience at Oracle Corporation in pharmaceutical consulting; Palo Alto VA Hospital as a biomedical engineer; and as founding or interim CEO for several Vivo portfolio companies
•	B.S. and M.S. in Electrical Engineering, Stanford; M.D. and Ph.D. in Neuroscience, UCLA Medical School

Steve Elms Managing Director, Aisling Capital http://www.aislingcapital.com
•	Serves as a director of Advion BioSciences, Inc., Ambit Biosciences Corporation, Avera Pharmaceuticals, Inc., Bioenvision, Inc., CeNeRx BioPharma, Inc. and MAP Pharmaceuticals, Inc., Archimica Coöperatief U.A., and NextWave Pharmaceuticals, Inc.
•	Former Principal in the Life Sciences Investment Banking Group of H&Q
•	Prior experience as a trader of mortgage-backed securities at Donaldson, Lufkin & Jenrette for two years
•	B.A. in Human Biology, Stanford; M.B.A. from the Kellogg School of Management at Northwestern University.

James Glasheen, Ph.D. General Partner, Technology Partners http://www.technologypartners.com
•	Former Managing Director at CIT Venture Capital, leading the Group's efforts in Life Science investing
•	Former leader within McKinsey & Company's Pharmaceutical and Medical Products Practice
•	Advisor to National Science Foundation (NSF) Small Business Innovation Research (SBIR) program
•	B.S. In Biology/Mechanical Engineering, Duke; M.A. and Ph.D. in Biology, Harvard University

David M. Mauney, MD Managing Director, De Novo Ventures http://www.denovovc.com
•	Co-founder of De Novo Ventures
•	Serves on the boards of Articulinx, Applied Spine, ProMed, Simpirica, Spectragenics, VeinRx and Ventus Medical
•	Former partner at Asset Management Company, where he worked with Pitch Johnson as the lead partner in healthcare investments.
•	Former director of Business Development for Fox Hollow Technologies
•	BA, Duke; M.D., Dartmouth School of Medicine

Jeffrey M. Nugent, Chairman President and CEO, Ventus Medical http://www.ventusmedical.com
•	Former President and Chief Executive Officer, Revlon, Inc.
•	Former President and Chief Executive Officer, Neutrogena Corp.
•	Vice President of Worldwide Quality Management, Director of Marketing for Health Care Consumer Products, and Director of Research & Development for Johnson & Johnson